Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

MacroGenics (M55) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Mgc030Colorectal Cancer, Pancreatic Cancer, Urothelial Cancer, Esophageal Cancer, Gastroesophageal Cancer, Gastric Cancer (Gc)Phase IRecruitingA Study of MGC030 in Participants With Advanced Solid TumorsSep 10, 2026―
LorigerlimabPlatinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Endometrial Cancer, Platinum-Resistant Ovarian Cancer, Clear Cell Adenocarcinoma Of Ovary, Clear Cell Adenocarcinoma Of Vulva, Clear Cell Adenocarcinoma Of Vagina, Clear Cell Adenocarcinoma Of Cervix, Clear Cell Adenocarcinoma Of Uterus, Clear Cell Adenocarcinoma Of Fallopian Tube, Clear Cell Adenocarcinoma Of PeritoneumPhase IIRecruitingA Study of Lorigerlimab in Participants With Advanced Solid TumorsDec 09, 2024
Mgc028Advanced Solid Tumors, Colorectal Carcinoma, Pancreatic Carcinoma, Cholangiocarcinoma, Nsclc AdenocarcinomaPhase IRecruitingA Study of MGC028 in Participants With Advanced Solid TumorsDec 04, 2024
Mgc026 Dose Escalation, Mgc026 Dose For ExpansionCervical Cancer, Ovarian Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Breast Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Sarcoma, Pancreas Cancer, Small-cell Lung Cancer, Gastric Cancer, Hepatocellular Carcinoma, Clear Cell Renal Cell Carcinoma, Advanced Cancer, Metastatic Cancer, Endometrial Cancer, Squamous Cell Carcinoma Of Head And Neck, Platinum-Resistant Ovarian Cancer, Castration Resistant Prostatic Cancer, Gastro-Esophageal Cancer, Esophageal Squamous Cell Cancer (Scc)Phase IRecruitingA Study of MGC026 in Participants With Advanced Solid TumorsJan 12, 2024
Docetaxel, Prednisone, LorigerlimabAndrogen-Independent Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Prostate Cancer Recurrent, Androgen-Independent Prostatic Neoplasms, Androgen-Insensitive Prostatic Cance, Immune Checkpoint Inhibitor, Inhibitory Checkpoint MoleculePhase IICompletedA Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerApr 17, 2023
Enzalutamide, Abiraterone, Vobramitamab Duocarmazine 2.0 Mg, Vobramitamab Duocarmazine 2.7 Mg, Vobramitamab DuocarmazineMelanoma, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head And Neck Squamous Cell Carcinoma, Malignant Melanoma, Castration-Resistant Prostatic Cancer, Carcinoma, Squamous Cell Of Head And Neck, Anal Cancer, Anal Neoplasm, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Non-Small Cell Carcinoma, Small Cell CarcinomaPhase IICompletedA Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsSep 19, 2022―
Mgd024Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm, Classical Hodgkin Lymphoma, Chronic Myeloid Leukemia, Leukemia, Acute Myeloid, Leukemia, B-Cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive SystemicPhase IActive Not RecruitingA Study of MGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesMay 02, 2022
Mgd020, Mgd014Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1Phase ICompletedA Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral TherapyFeb 18, 2022―
Vobramitamab Duocarmazine, LorigerlimabEpithelial Ovarian Cancer, Advanced Solid Tumor, Renal Cell Carcinoma, Malignant Melanoma, Castration-Resistant Prostatic Cancer, Hepatocellular Cancer, Pancreatic Ductal CarcinomaPhase ICompletedA Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsFeb 12, 2022―
Imgc936Advanced Solid Tumorphase1AndPhase2CompletedFirst-in-Human Study of IMGC936 in Participants With Advanced Solid TumorsOct 27, 2020―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does MacroGenics Inc (CH:M55) have in its pipeline
MacroGenics CH:M55 is currently developing the following drugs: Mgc030, Lorigerlimab, Mgc028, Mgc026 Dose Escalation, Mgc026 Dose For Expansion, Docetaxel, Prednisone, Lorigerlimab, Enzalutamide, Abiraterone, Vobramitamab Duocarmazine 2.0 Mg, Vobramitamab Duocarmazine 2.7 Mg, Vobramitamab Duocarmazine, Mgd024, Mgd020, Mgd014, Vobramitamab Duocarmazine, Lorigerlimab, Imgc936, Trastuzumab, Chemotherapy, Retifanlimab, Margetuximab, Tebotelimab, Vobramitamab Duocarmazine, Pembrolizumab, Margetuximab 10 Mg/Kg, Margetuximab 15 Mg, Trastuzumab, Margetuximab, Physician's Choice Of Chemotherapy., Pembrolizumab, Retifanlimab, Enoblituzumab Schedule 1, Enoblituzumab Schedule 2, Margetuximab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.